Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 16/20 | 0.69 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 5/20 | 0.49 |
| ▸ | F2 | P00734 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5989502 | 0.86 | ELANE (0.73) | ELANESCN9APLAUF2 | |
| SCHEMBL2432444 | 0.81 | ELANE (0.74) | ELANEPLAUF2 | |
| SCHEMBL28076707 | 0.79 | PDGFRA (0.62) | ELANEPLAUF2POLB | |
| SCHEMBL260569 | 0.79 | KDM4E (0.60) | ELANESCN9AEGFRSRC | |
| SCHEMBL29789796 | 0.79 | KDM4E (0.60) | ELANESCN9AEGFRSRC | |
| SCHEMBL726679 | 0.77 | ELANE (0.60) | ELANEPLAUF2POLB | |
| SCHEMBL28171820 | 0.77 | ELANE (0.61) | ELANESCN9AEGFRSRC | |
| SCHEMBL21958613 | 0.77 | ELANE (0.61) | ELANESCN9APLAUF2EGFR | |
| SCHEMBL3428613 | 0.77 | ELANE (0.72) | ELANEPLAUF2 | |
| SCHEMBL2638010 | 0.76 | ELANE (0.65) | ELANEPLAUF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120130078-A1 | INDAZOLE DERIVATIVES AS ADENOSINE MONOPHOSPHATE DEAMINASE (AMPD) INHIBITORS FOR USE IN DIABETES AND RELATED DISEASES OF METABOLIC SYNDROME | OCHS RAYMOND S (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120130078-A1 | INDAZOLE DERIVATIVES AS ADENOSINE MONOPHOSPHATE DEAMINASE (AMPD) INHIBITORS FOR USE IN DIABETES AND RELATED DISEASES OF METABOLIC SYNDROME | OCHS RAYMOND S (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130078-A1 | INDAZOLE DERIVATIVES AS ADENOSINE MONOPHOSPHATE DEAMINASE (AMPD) INHIBITORS FOR USE IN DIABETES AND RELATED DISEASES OF METABOLIC SYNDROME | AMPD1, AMPD3, AMPD2 | ELANE 3999/4885SCN9A 3313/4885PLAU 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.